FDA Approves First Drug To Treat Neurological Symptoms Of Type 3 Gaucher Disease

The FDA has approved the first treatment for the neurological symptoms of Type 3 Gaucher disease, offering a new option for patients with a rare inherited disorder that affects the brain and nervous system.

The medication, Infilbray, also known as venglustat, is approved for adults and children weighing at least 33 pounds. The approval was granted to Genzyme Corporation, a Sanofi company.

Gaucher disease prevents the body from properly breaking down certain fatty substances. In Type 3, those substances can build up in the brain, causing problems with balance, coordination, speech, memory and thinking.

The new approval is specifically for Type 3 Gaucher disease. Unlike Type 1, this form of the disease affects the brain and nervous system.

Infilbray can cross the blood-brain barrier and is designed to reduce the buildup of those substances in the body and brain.

The FDA based its decision on a 52-week study involving 43 patients ages 12 and older whose non-neurological symptoms had been stabilized with enzyme replacement therapy. Patients receiving Infilbray showed improvement on a combined measure of coordination and cognitive function compared with patients continuing enzyme replacement therapy.

The treatment also carries important safety risks. The FDA says serious psychiatric effects, including suicidal thoughts and behavior, have been reported. The prescribing information also warns of possible lens clouding in children and potential harm to an unborn baby based on animal studies.

Common side effects include gastrointestinal symptoms and effects on mood. Treatment must be started and supervised by a healthcare provider experienced in managing Type 3 Gaucher disease.

 

Join the official TLS Community

This content, and any other content on TLS, may not be republished or reproduced without prior permission from TLS. Copying or reproducing our content is both against the law and against Halacha. To inquire about using our content, including videos or photos, email us at [email protected].

Stay up to date with our news alerts by following us on Twitter, Instagram and Facebook.
Got a news tip? Email us at [email protected], Text 415-857-2667, or WhatsApp 609-661-8668.
Subscribe
Notify of

Answer the question below to prove you\'re human *

0 Comments
Inline Feedbacks
View all comments

0
Would love your thoughts, please comment.x
()
x